Ingmar Hoerr

Ingmar Hoerr (b. 1968) is a German biologist. He is the seminal early mRNA pioneer and one of the founders of CureVac.

Biography

In 2000 Hoerr published his doctoral thesis entitled RNA vaccine for the induction of specific cytotoxic T-lymphocytes (CTL) and antibodies. In this work, he discovered that ribonucleic acid can be stabilized. This discovery made it easy to use ribonucleic acid for the development of vaccines and immunotherapies. Then Hoerr together with colleagues from the lab groups of Günther Jung and Hans-Georg Rammensee founded the biopharmaceutical company CureVac.[1]

In 2018 he gave up his office as Chairman of the Board and changed - as Chairman - to the Supervisory Board. Daniel L. Menichella was hired in that position in order to develop R&D and plants in the U.S., but the board changed its mind in 2020 and fired Menichella.[2]

On March 11, 2020, Hoerr took over the position of CEO again at CureVac,[3] replacing his interim successor Menichella.[4] Hoerr was replaced by Jean Stephenne as chairman of the supervisory board. In August 2020, Franz-Werner Haas replaced Hoerr (who had a severe health issue in march 2020) as Chief Executive Officer. [5]

References
  1. "About CureVac". CureVac.
  2. "Jean Stéphenne (CureVac): "Les essais du vaccin anti-Covid-19 vont débuter en juin en Allemagne et en Belgique"". www.lecho.be.
  3. "Company Founder Ingmar Hoerr Succeeds Daniel Menichella as CEO of CureVac AG | English". CureVac.
  4. Oltermann, Philip (March 15, 2020). "Trump 'offers large sums' for exclusive US access to coronavirus vaccine" – via www.theguardian.com.
  5. "CureVac Appoints Dr. Franz-Werner Haas as Chief Executive Officer and Dr. Igor Splawski as Chief Scientific Officer". CureVac. August 4, 2020.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.